Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.43 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8990848 | 0.93 | L3MBTL1 (0.58) | LMNAL3MBTL1MAOBGCGRMAPK14 | |
| SCHEMBL13925528 | 0.92 | — | — | |
| SCHEMBL131869 | 0.92 | — | — | |
| Ammonia Solution, Strong SCHEMBL143304 | 0.89 | LMNA (0.70) | LMNAL3MBTL1IDO1LOXL2ALDH1A1 | |
| SCHEMBL1702558 | 0.86 | TP53 (0.56) | L3MBTL1ALDH1A1TP53EGFRTAAR1 | |
| SCHEMBL2776957 | 0.86 | TP53 (0.56) | L3MBTL1ALDH1A1TP53EGFRTAAR1 | |
| SCHEMBL18721350 | 0.84 | LMNA (0.64) | LMNAL3MBTL1IDO1LOXL2ALDH1A1 | |
| SCHEMBL12603779 | 0.84 | L3MBTL1 (0.64) | LMNAL3MBTL1MAOBIDO1LOXL2 | |
| SCHEMBL13282199 | 0.83 | CYP17A1 (0.47) | LMNAL3MBTL1MAOBGCGRMAPK14 | |
| SCHEMBL19300894 | 0.83 | RXRA (0.50) | LMNAL3MBTL1MAOBGCGRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3331965-B1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2022-01-05 | — | — | EP | disclosed |
| EP-3922639-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | UNIV RUTGERS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180223187-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-20180223187-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-20180142154-A1 | LIQUID CRYSTAL COMPOSITION HAVING GOOD PHOTOSTABILITY AND THERMOSTABILITY, AND LIQUID CRYSTAL DISPLAY ELEMENT | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20080303002-A1 | DISPLAY MATERIAL AND AUTOMOBILE MEMBER | FUJIFILM CORPORATION (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080300405-A1 | Naphthalenetetracarboxylic Aicd Derivatives and their Use as Semiconductors | BASF SE (DE) | 2008-12-04 | — | — | US | disclosed |
| EP-1966206-A1 | NAPHTHALENETETRACARBOXYLIC ACID DERIVATIVES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007074137-A1 | NAPHTHALENETETRACARBOXYLIC ACID DERIVATIVES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2007-07-05 | — | — | WO | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| US-4027041-A | Ethyl- and vinylbenzenes as antithrombotic agents | ELI LILLY AND COMPANY (US) | 1977-05-31 | — | — | US | disclosed |
| US-4024284-A | Ethyl- and vinylbenzenes as anti-inflammatory agents | ELI LILLY AND COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
| US-3975542-A | Ethyl- and vinylbenzenes as antithromobiotic agents | ELI LILLY AND COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3975543-A | Ethyl- and vinylbenzenes as anti-inflammatory agents | ELI LILLY AND COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031624-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC10A1, SLC47A1 | LMNA 4360/4885L3MBTL1 3913/4885MAOB 3108/4885 |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | LMNA 4599/4885L3MBTL1 4855/4885MAOB 2710/4885 |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | LMNA 3772/4885L3MBTL1 4546/4885MAOB 24/4885 |
| US-20080300405-A1 | Naphthalenetetracarboxylic Aicd Derivatives and their Use as Semiconductors | ADSL, ALAD, EED | LMNA 2657/4885L3MBTL1 4486/4885MAOB 3091/4885 |
| US-20190248840-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | LMNA 2969/4885L3MBTL1 781/4885MAOB 3290/4885 |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | LMNA 2969/4885L3MBTL1 781/4885MAOB 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.